Misoprostol Treatment of Incomplete Abortion by Midwives and Physicians in Uganda
NCT ID: NCT01743508
Last Updated: 2017-08-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
731 participants
INTERVENTIONAL
2012-04-30
2017-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Women with incomplete abortion will be randomly allocated to undergo a clinical assessment and treatment (MVA or misoprostol) either by physician or midwife with safety and efficacy as main outcomes in a RCT carried out in hospital setting in Uganda. Our hypothesis is that there are no significant differences in effectiveness and safety between manual vacuum aspiration and misoprostol treatment of incomplete abortion provided by physicians and midwife.
The involvement of midlevel providers in treatment of incomplete abortion has previously not been systematically evaluated in African health care setting.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Misoprostol Treatment of Mid Trimester Incomplete Abortion by Midwives and Doctors in Uganda.
NCT03622073
Task Sharing to Improve Post Abortion Care at District Health Care Level- Trial in Uganda
NCT01844024
Combating Maternal Mortality in Uganda: An Assessment of the Role of Misoprostol in Prevention of Post-Partum Hemorrhage
NCT01866241
Post-abortion Care and Contraceptive Counselling by Midwives or Physicians
NCT01865136
Misoprostol for Preventing Postpartum Hemorrhage
NCT00124540
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Misoprostol by physician
Misoprostol treatment by midwife
Misoprostol treatment by midwife
Misoprostol treatment by midwife
Misoprostol by midwife
Misoprostol treatment by midwife
Misoprostol treatment by midwife
Misoprostol treatment by midwife
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Misoprostol treatment by midwife
Misoprostol treatment by midwife
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Contractions during pregnancy
Exclusion Criteria
* Uterine size more than 12 weeks of gestation
* Suspected ectopic pregnancy
* Unstable hemodynamic status and chock
* Signs of pelvic infection and/or sepsis
15 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Karolinska Institutet
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marie Klingberg-Allvin
Researcher
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Elisabeth Faxelid, Professor
Role: PRINCIPAL_INVESTIGATOR
Karolinska Institutet
Kristina Gemzell-Danielsson, Professor
Role: PRINCIPAL_INVESTIGATOR
Karolinska Institutet
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mulago Hospital
Kampala, , Uganda
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ZZK9elifax
Identifier Type: OTHER
Identifier Source: secondary_id
Sida_2010
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.